Jeff Settleman joins Pfizer to head oncology R&D

6 June 2019

Pfizer (NYSE: PFE) has announced that Jeff Settleman (pictured above) has joined the company as senior vice president and group head of Oncology Research and Development.

He will be based at the US drug giant’s site in La Jolla, California, starting on July 1. He joins from Calico Life Sciences, where his job title is distinguished principal investigator and head of oncology research.

Prior to Calico, Dr Settleman led Discovery Oncology at Genentech, and he has had a distinguished career as an academic scientist including with the Whitehead Institute for Biomedical Research at Massachusetts Institute of Technology and at Harvard School of Medicine, where he spent 18 years.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK